ElendiLabs Logo
Back to Articles

Local Regulatory Experts

Connect with regulatory affairs consultancies specializing in this region.

Qualtech Consulting Corporation

Taiwan, China, Japan, Singapore, Hong Kong, Malaysia, Philippines, Vietnam, Australia, Germany, Korea, Thailand, USA

Registration

A specialized medical device consulting firm offering a one-stop solution for complex global regulatory challenges. We offer real-time regulatory and clinical support, local representation, and QMS services across 13 markets, ensuring efficient market entry and compliance.

Registrar Corp

Hampton, Virginia (HQ), Shenzhen, China, London, United Kingdom, Paris, France, Madrid, Spain, Hyderabad, India, Kuala Lumpur, Malaysia, Tel Aviv, Israel, Guatemala City, Guatemala, Cape Town, South Africa

Registration

A global FDA compliance firm assisting businesses in the food, medical device, drug, and cosmetic industries with registration, U.S. Agent services, labeling, and regulatory software solutions.

ARQon Pte. Ltd.

Singapore (HQ), Malaysia, Vietnam, Indonesia, Philippines, Thailand, Taiwan, Hong Kong, South Korea, Switzerland, USA, Australia, New Zealand, Rwanda, India, Sri Lanka

Registration

We are a premier regulatory consultancy firm specializing in medical devices, in-vitro diagnostics (IVD), and pharmaceuticals. Founded in 2014, the company offers a comprehensive suite of services ranging from product development strategy and clinical trials to product registration and post-market surveillance. With a team of experts possessing vast experience in regulatory authorities and industry, we bridge the gap between scientific innovation and regulatory compliance, ensuring patient safety while fostering medical advancement. The company also provides unique business matching services through its ATTOPOLIS platform and training through the International Medical Device School.

EPSI GLOBAL PTE. LTD.

Singapore (HQ), Kuala Lumpur, Malaysia, Jakarta, Indonesia, Bangkok, Thailand, Hanoi, Vietnam, Manila, Philippines, Shanghai, China

Registration

We provide end-to-end regulatory solutions covering all classes of medical devices and IVDs in major APAC markets, especially the ASEAN region (Singapore, Malaysia, Indonesia, Thailand, Vietnam, Philippines) and major Northeast Asian markets (China, Korea, Japan). Services include classification, registration, local authorized representation, quality management system (QMS) implementation/auditing (ISO 13485/local GMP), and post-market surveillance. Their local presence minimizes market entry risks and time-to-market.

View More Consultancies in This Region
Post Market Surveillance

June 16, 2025

Approximately 5 minutes

Post-Market Surveillance and Adverse Event Reporting in Malaysia: MDA Vigilance Requirements

Post-Market Surveillance and Adverse Event Reporting in Malaysia: MDA Vigilance Requirements

Post-Market Surveillance (PMS) is a mandatory requirement for all manufacturers selling medical devices in Malaysia. This vigilance system is enforced by the Medical Device Authority (MDA) under the Medical Device Act 2012 and the Medical Device (Duties and Obligations of Establishment) Regulations 2019. Failure to comply with these requirements, which are similar to those in the ASEAN Medical Device Directive (AMDD), can result in product recall or loss of market access.


The Role of the Authorized Representative

The Malaysia Authorized Representative (AR), or license holder, whose details are listed on the product's registration certificate, holds a critical responsibility in the PMS process. The AR is the legally responsible entity for communicating with the MDA on behalf of the foreign manufacturer regarding all post-market vigilance issues, including Adverse Event (AE) reporting and Field Safety Corrective Actions (FSCAs).

Criteria for Reportable Adverse Events (AEs)

An event is considered a reportable Adverse Event (AE) only if three core criteria are met:

  1. An Adverse Event has occurred.
  2. The medical device is associated with the Adverse Event.
  3. The Adverse Event led to one of the following serious outcomes:
    • A serious threat to public health.
    • Death or serious deterioration in the state of health of a patient, user, or other person.
    • No death or serious injury occurred, but the event, if it recurs, might lead to death or serious injury of a patient, user, or other person.

Mandatory Reporting Timelines

All Adverse Events must be reported to the MDA immediately and within the following specific timeframes, calculated from the moment the manufacturer or their AR becomes aware of the event:

Event TypeReporting Deadline
Serious threat to public healthNot later than 48 hours
Death or serious deterioration in state of healthNot later than 10 days
Recurrence might lead to death or serious injuryNot later than 30 days

Post-Market Corrective Actions (FSCAs)

In addition to reporting, manufacturers are obligated to implement Field Safety Corrective Actions (FSCAs) if necessary. The AR is responsible for managing the communication and implementation of these corrective actions in collaboration with the MDA to ensure device safety and compliance in the Malaysian market.

Need Expert Guidance?

Contact us at contact@elendilabs.com / +852 4416 5550